Trials

Study Number Title Indication Marker Status
Bioluma

A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition.

Cohort 1: Subjects with histologically or cytologically confirmed advanced non-squamous non-small cell lung cancer who present with stage IIIB/IV disease after failure of platinum-based first-line therapy (second line) – recruitment of cohort 1 is stopped

Cohort 2: Subjects with histologically or cytologically confirmed limited-stage or extensive-stage small cell lung cancer and high tumor mutation burden after failure of platinum-based first-line therapy (second line).

no marker Active Trial
Theros

Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinib

EGFR-mutated non-small-cell lung cancer (NSCLC) with acquired TKI resistance to erlotinib, gefitinib or afatinib who are “unknown” for EGFR T790M status due to non-informative or unfeasible tumor rebiopsy, and a negative finding for EGFR T790M in a standard plasma genotyping assay.

EGFR Active Trial
TRIDENT

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Histologically confirmed locally advanced/metastatic (stage IIIB or IV per AJCC/IASLC v. 8) NSCLC as first-line setting.

NTRK, ROS1 Active Trial
CINC280J12201

A double-blind, Placebo controlled, randomized, Phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and Placebo as first line Treatment for locally advanced or metastatic non-small cell lung Cancer patients with MET exon 14 skipping mutations.

Histologically or cytologically confirmed and documented stage IIIB, IIIC or IV unresectable, squamous or non-squamous NSCLC which is in Addition:
a) harboring MET exon 14 skipping mutations, as determined by central pre-screening assessment performed at a Novartis designated lab, of not previously determined locally
b) Negative for any mutations that are known to sensitize to EGFR Inhibitors, such as exon19 deletions or L858R Substitution
c) Negative for ALK rearrangements

MET Active Trial
EATON

An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer, activating EGFR mutation and resistance to 1st, 2nd or 3rd generation EGFR TKI therapy

Patients with advanced non-small cell lung cancer harbouring sensitizing EGFR mutations (EGFR del19 or EGFR p.L858R) with progression upon treatment with 1st or 2nd generation EGFR TKI and acquired resistance mutation EGFR p.T790M

EGFR Active Trial
LOXO-RET-18037

A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

Patients with a locally advanced or metastatic solid tumor with RET activation

RET Active Trial
Loxo Phase III – J2G-MC-JZJC

LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-SmallCell Lung Cancer

Histologically or cytologically confirmed diagnosis of locally advancedor metastatic solid tumor (including primary CNS tumors; Stage IV, that harbors a ROS1 or NTRK1-3 gene fusion.

ALK, NTRK, ROS1 Active Trial
FIND

A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced squamous NSCLC (sqNSCLC) harboring FGFR genetic alterations after relapse of standard therapy.

Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients)
Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients)
Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)

FGFR Active Trial
STARTRK-2

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3 or ROS1 Gene Rearrangements.

Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3 or ROS1 gene rearrangement that is predicted to translate into a fusion protein with a functional TrkA/B/C or ROS1 kinase domain, respectively, without a concomitant second oncodriver (e.g., EGFR, KRAS). These are patients for whom no alternative effective standard therapy is available or for whom standard therapy is considered unsuitable or intolerable.

NTRK Trial in preparation